Dare Bioscience Inc (DARE)is dedicated to the development of innovative products in women’s health. The company stock was up 31.36% to $3.1 in the after-market session.
What they do…
The company’s mission is to identify, develop and market a diverse portfolio of differentiated therapies for women, mainly in the areas of contraception, vaginal health, sexual health, and fertility.
- Top 3 Cloud Computing Stocks to Watch For in 2021
- 3 Best Work-From-Home Stocks for Long-term Investment
While the latest rally in the Corporate Universe stock is extremely impressive, nothing material related to the company’s business was announced that could have prompted such a move. Thus, it could be necessary to see something that took place in a recent couple of months.
January 05, 2021, Daré Bioscience Inc., a pioneer in research in women’s health (NASDAQ: DARE), announced that its Founder and Chief Executive Officer, Sabrina Martucci Johnson, is engaging in a fireside chat at the H.C. Wainwright Interactive Conference BIOCONNECT 2021 on 11-14 January 2021.
December 7, 2020, DARE-BVFREE phase 3 randomised, double aveugled, placebo-controlled clinical trial assessment of DARE-BV1 among 307 women afflicted with bacterial vaginosis, a severe disease projected to affect approximately 21 million females in the United States, was disclosed by Daré Bioscience, Inc. (NASDAQ: DARE). DARE-BV1 is a research thermosetting bioadhesive hydrogel containing clindamycin phosphate 2 percent and is intended to be used as an easy, one-time vaginal bacterial vaginosis treatment. The trial found its primary outcome that a single DARE-BV1 administration was superior to placebo as the key clinical tool for bacterial vaginosis diagnosed women.